---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-113064"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:14:19.173261+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phibro completes $350M acquisition of Zoetis' medicated feed additive portfolio

## Summary
- Acquired >37 product lines across ~80 countries, six manufacturing sites in US, Italy, China, and >300 employees.
- Funded with $350M cash: $189M Delayed Draw Term A-1 Loans and $161M A-2 Loans under existing credit agreement.
- Expected to boost profitability, EBITDA margin, and be accretive to adjusted EPS; more details on Nov 7 Q1 call.
- Portfolio complements Phibro's vaccines, nutritional specialties, and mineral nutrition.

## SEC filing metadata
- accession: 0001104659-24-113064
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01, 2.03, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465924113064/0001104659-24-113064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465924113064/tm2427228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-113064
- JSON: https://secwatch.observer/filing/0001104659-24-113064.json
- Plain text: https://secwatch.observer/filing/0001104659-24-113064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.